Alexander Lesokhin
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexander Lesokhin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07454382 · A Study of Elranatamab and Cyclophosphamide in People With Multiple MyelomaMemorial Sloan Kettering Cancer Center · recruiting · Multiple Myeloma · principal investigator
- Ph1NCT05139225 · A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple MyelomaMemorial Sloan Kettering Cancer Center · completed · Multiple Myeloma · principal investigator
- Ph1NCT03196401 · A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone PlasmacytomaMemorial Sloan Kettering Cancer Center · withdrawn · Solitary Bone Plasmacytoma · principal investigator
- Ph2NCT02538198 · Lenalidomide Maintenance in Plasma Cell MyelomaMemorial Sloan Kettering Cancer Center · active not recruiting · Plasma Cell Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:23 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- 1,575 citationsRCR 84.7
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.J Clin Oncol · 2016874 citationsRCR 27.2
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Nat Med · 2023617 citationsRCR 54.5
- GPRC5D-Targeted CAR T Cells for Myeloma.N Engl J Med · 2022385 citationsRCR 25.1
- Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.Blood · 2017168 citationsRCR 5.0
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.Nat Med · 2023152 citationsRCR 13.2
- A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.Blood · 2017146 citationsRCR 4.6
- 105 citationsRCR 5.2
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.Lancet Haematol · 202189 citationsRCR 4.8
- A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.Leukemia · 202184 citationsRCR 4.1